Taking a closer look. Making a bigger impact.
MSK-IMPACT® is a targeted DNA sequencing test available to cancer patients. It can detect mutations and other critical changes in the most important cancer genes using DNA from tumor tissue and matched healthy cells.
MSK-ACCESSSM is a “liquid biopsy” test that can detect many of these same mutations with ultra-high sensitivity in cell-free DNA collected from blood plasma.
Both tests are used in precision diagnosis as well as for matching patients to available therapies or clinical trials that will benefit them most.
To learn more about distinguishing product features, validation methods, and the underlying value of these two tests, see here.
For licensing information, please contact: